Exhibit 99.1

APPOINTMENT OF JOINT COMPANY SECRETARY

Melbourne, Australia; April 6 and New York, USA; April 6, 2022: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Paul Hughes has been appointed as Joint Company Secretary of Mesoblast Limited, joining the existing Company Secretary, Ms Niva Sivakumar. Mr Hughes and Ms Sivakumar are jointly responsible for the Company Secretary role for Mesoblast and are the persons responsible under Listing Rule 12.6 for communications with the ASX.

Ms Sivakumar was appointed as Company Secretary of Mesoblast Limited in October 2019. Mr Hughes began working with Mesoblast in February 2019 following a long career as an investment banker and corporate advisor. He has served as Mesoblast’s Global Head of Corporate Communications since December 2020.

Release authorized by the Chief Executive.

For more information, please contact: